HDR Gateway logo
HDR Gateway logo

Bookmarks

Optimum Patient Care

Optimum Patient Care

Introduction

{"type":"doc","content":[{"type":"paragraph","content":[{"type":"text","text":"The "},{"type":"text","marks":[{"type":"bold"}],"text":"Optimum Patient Care Research Database (OPCRD)"},{"type":"text","text":" is a leading UK electronic medical record (EMR) database, owned and maintained by "},{"type":"text","marks":[{"type":"bold"}],"text":"Optimum Patient Care Limited (OPCUK) "},{"type":"text","text":"and an EHDEN data partner, having completed the OMOP CDM mapping in 2023 (v5.4.1). With de-identified health information from over 27 million patients across 1,175+ primary care sites, OPCRD offers an unparalleled resource for healthcare research and innovation. Its extensive dataset includes a wide range of patient information, including demographics, diagnoses, symptoms, treatments, test results, referrals, and patient-reported outcomes, providing insights into approximately 37% of the UK population."}]},{"type":"paragraph","content":[{"type":"text","text":" "}]},{"type":"paragraph","content":[{"type":"text","text":"Approved for use by the NHS Health Research Authority (HRA) Research Ethics Committee (REC Reference: 20/EM/0148), OPCRD is a trusted resource for medical research, underpinning over 110 published studies in clinical care, public health, and pharmaceuticals. The database is overseen by an independent committee, ensuring ethical, secure, and compliant use of anonymised data for research purposes."}]},{"type":"paragraph","content":[{"type":"text","text":" "}]},{"type":"paragraph","content":[{"type":"text","text":"OPCUK also owns and maintains global databases that would enrich the research beyond OPCRD."}]},{"type":"bulletList","content":[{"type":"listItem","content":[{"type":"paragraph","content":[{"type":"text","text":"International Severe Asthma Registry: 34,000+ patients from more than 250 sites across 32 countries"}]}]},{"type":"listItem","content":[{"type":"paragraph","content":[{"type":"text","text":"OPCRD-Australia: 950,000+ patients across 22 primary care sites"}]}]},{"type":"listItem","content":[{"type":"paragraph","content":[{"type":"text","text":"OPCRD-US: 120 sites across 3 integrated healthcare systems"}]}]}]}]}
https://www.optimumpatientcare.org/

Datasets (1)

Optimum Patient Care Research Database (OPCRD)
Dataset population size: 24,878,083
Health and disease

Publications (117)

Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success.
Müllerová H, Chan JSK, Heatley H, Carter V, Townend J, Skinner D, Franzén S, Marshall J, Price D.
Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis.
Menzies-Gow AN, Tran TN, Stanley B, Carter VA, Smolen JS, Bourdin A, Fitzgerald JM, Raine T, Chapaneri J, Emmanuel B, Jackson DJ, Price DB.
The Association Between Short-Acting β<sub>2</sub>-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia.
Price D, Jenkins C, Hancock K, Vella R, Heraud F, Le Cheng P, Murray R, Beekman M, Bosnic-Anticevich S, Botini F, Carter V, Catanzariti A, Doan J, Fletton K, Kichkin A, Le T, Le Lievre C, Lau CM, Novic D, Pakos J, Ranasinghe K, Roussos A, Samuel-King J, Sharma A, Stewart D, Willet B, Bateman E, OPCA Improving Asthma Outcomes in Australia Research Group.
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS.
Price D, Henley W, Cançado JED, Fabbri LM, Kerstjens HAM, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Nudo E, Carter V, Skinner D, Vella R, Soriano JB, Kots M, Georges G.
Patterns of care in the management of high-risk COPD in the US (2011-2019): an observational study for the CONQUEST quality improvement program.
Kerr M, Tarabichi Y, Evans A, Mapel D, Pace W, Carter V, Couper A, Drummond MB, Feigler N, Federman A, Gandhi H, Hanania NA, Kaplan A, Kostikas K, Kruszyk M, van Melle M, Müllerová H, Murray R, Ohar J, Pollack M, Pullen R, Williams D, Wisnivesky J, Han MK, Meldrum C, Price D.
Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma.
Heatley H, Tran TN, Bourdin A, Menzies-Gow A, Jackson DJ, Maslova E, Chapaneri J, Skinner D, Carter V, Chan JSK, Ariti C, Haughney J, Price DB.